Skip to main content

Table 1 Patient Demographics and Clinical Characteristics

From: Insight into the current practice of ototoxicity monitoring during cisplatin therapy

Characteristic N (%)
Sex
 Male 216 (60)
 Female 163 (40)
Malignancy type
 Breast 3 (0.8)
 Central Nervous System 12 (3.2)
 Gastrointestinal 32 (8.4)
 Gynecologic 74 (19.5)
 Head & Neck 122 (32.2)
 Hematologic 3 (0.8)
 Lung 51 (13.5)
 Sarcoma 7 (1.8)
 Skin 5 (1.3)
 Urologic 70 (18.5)
Treatment intent
 Curative 305 (80.5)
 Palliative 65 (17.2)
 Unknown 9 (2.3)
History of Prior Radiation to Head and Neck
 Yes 16 (4.2)
 No 312 (82.3)
 Unknown 51 (13.5)
Concurrent Radiation Treatment
 Yes 204 (53.8)
 No 175 (46.2)
History of Hearing Loss prior to treatment
 Yes 104 (27.4)
 No 183 (48.3)
 Unknown 92 (24.3)